+86-28-82633987
Product name: Eriodictyol
Synonym name:
Catalogue No.: BP0555
Cas No.: 552-58-9
Formula: C15H12O6
Mol Weight: 288.255
Physical Description:
Type of Compound: Flavonoids
Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
The product could be supplied from milligrams to grams, upto kilograms.
Inquire for bulk scale.
Description:
Eriodictyol is a flavanone characteristic of lime, found mainly in juice. The glycosylated forms are eriocitrin (bound to a rutinoside) and neoeriocitrin (bound to a neohesperidose).
Eriodictyol prevents some secondary effects of diabetes, such as diabetic retinopathy and biochemical changes in plasma (study in rats) (Bucolo et al., 2012). In addition, it has been reported that in in vitro studies, eriodictyol decreases insulin resistance and glucose absorption.
HPLC of Eriodictyol
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
107.2200
1.8614
1.5706
.3033
3.1293
2.1532
Low
84.5933
2.9937
No
No
Yes
No
Yes
No
0.6
Yes
No
Yes
No
Eriodictyol, CAS number 552-58-9, is a flavonoid natural compound widely found in various Chinese medicinal herbs and edible plants. As an important member of flavonoid compounds, sacrophilol has attracted widespread attention in pharmacology and natural product chemistry due to its remarkable antioxidant, anti-inflammatory, and antiviral activities. In recent years, with further research into its molecular mechanisms, the potential value of sacrofenol in the treatment of various diseases such as antitumor and antiviral has gradually emerged, especially its induction of the Nrf2 signaling pathway and its efficient inhibition of influenza-dependent RNA polymerase, providing a solid theoretical foundation for its clinical development.
This paper aims to systematically review the chemical structure and physicochemical properties of sacrofenol, plant origins and extraction methods, explore its pharmacological activity and mechanism of action in depth, evaluate its druggability parameters and pharmacokinetic characteristics, and anticipate its potential and development direction in clinical application, providing references for subsequent related research and drug development.
Acetifol belongs to the flavonoid class of compounds with the specific structure of 3',4',5,7-tetrahydroxyflavanone. Its molecular formula is C15H12O6, and its molecular weight is 288.2550. The chemical structure of sacrophilol consists of a typical flavanone backbone with multiple hydroxyl substituents, which gives it excellent antioxidant activity. Its LogP value is 1.8614, showing moderate lipid solubility and facilitating penetration of cell membranes. The topological pole surface area (TPSA) is 107.22 Ų, indicating moderate polarity, which may affect its bioavailability and pharmacokinetic properties.
In terms of water solubility, sanchlorophenol has a water solubility of 0.3033 mg/mL, making it a low-solubility compound, which poses certain challenges for oral absorption and formulation development. The blood-brain barrier penetration ability is relatively low, suggesting that its role in the central nervous system may be limited. In safety evaluation, trichlorphenol did not show hERG channel inhibition; the Ames-induced mutagenic test result was 0.6, indicating low genotoxicity risk and a solid safety foundation.
Erythionol is widely found in various Chinese medicinal herbs and edible plants, with Eriodictyon being the main source. Common plants containing Eutrophetiol include Eriodictyon californicum, citrus fruits and their peels, and certain medicinal herbs such as Scutellaria baicalensis. Its content is greatly influenced by plant species, harvest time, geographical environment, and processing techniques.
The extraction method mainly uses organic solvent extraction combined with chromatography separation technology. Traditional extraction mostly uses ethanol or methanol aqueous solutions as extractants, improving extraction efficiency through ultrasound-assisted extraction or reflux extraction. Subsequently, purification was performed using silica gel column chromatography and reversed-phase high-performance liquid chromatography (RP-HPLC). In recent years, new technologies such as supercritical CO2 extraction and microwave-assisted extraction have been introduced, significantly improving extraction efficiency and purity, and better meeting green environmental protection requirements.
Acetiol exhibits a variety of significant pharmacological activities, covering antioxidant, anti-inflammatory, antiviral, and antitumor aspects.
As a polyhydroxyflavonoid, sachlorophenol has a powerful free radical scavenging ability. In vitro studies have shown that trichlorphenol can effectively eliminate hydroxyl radicals, superoxide anions, and hydrogen peroxide, reducing cellular damage caused by oxidative stress. Its antioxidant effect is partly attributed to inducing activation of the nuclear factor E2-related factor 2 (Nrf2) signaling pathway, which promotes the expression of antioxidant enzymes such as glutathione peroxidase (GPx) and superoxide dismutase (SOD), thereby enhancing intracellular antioxidant defense.
Chlorpophenol can significantly inhibit the release of inflammatory mediators, including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and nitric oxide (NO). Its mechanism involves inhibiting activation of the nuclear factor κB (NF-κB) signaling pathway, reducing the transcription expression of pro-inflammatory factors, thereby alleviating inflammatory responses. Animal model studies have shown that sacrophilol has protective effects against various inflammatory diseases such as arthritis and inflammatory bowel disease.
As an influenza-dependent RNA polymerase inhibitor, sacrofen demonstrates extremely high inhibitory activity, with an IC50 value of only 18 nM. This mechanism of action directly inhibits viral RNA polymerase activity, blocking viral replication and demonstrating strong antiviral potential against influenza. Additionally, there are preliminary reports of santhalol's inhibitory effects on other viruses such as respiratory syncytial virus (RSV) and certain coronaviruses, but the mechanism requires further elucidation.
Acetifol exhibits effects in various tumor cell lines by inhibiting proliferation, inducing apoptosis, and inhibiting migration and invasion. Its antitumor activity involves multiple signaling pathways and molecular targets, including MCL1, BCL2, STAT3, MMP2, TOP1, HIF1A, TOP2A, MAPK1, ESR1, and CYP19A1. By regulating these targets, sacrofenol can promote tumor cell apoptosis, inhibit tumor angiogenesis and metastasis, demonstrating multi-target, multi-mechanism anti-tumor potential.
Trichlorol's mechanisms of action are diverse, covering antioxidant, anti-inflammatory, antiviral, and antitumor aspects, mainly achieved by regulating key molecular targets and signaling pathways.
Nrf2 is a core regulatory factor of intracellular antioxidant defense. Olachlorol promotes the release of Nrf2 from the cytoplasm and translocates it to the nucleus, binding to antioxidant response elements (AREs), activating downstream antioxidant enzyme gene expression and enhancing cells' ability to resist oxidative stress. This mechanism not only explains its antioxidant activity but also provides a molecular basis for its anti-inflammatory and cell-protective effects.
Olachlor inhibits its enzyme activity by binding to the influenza virus-dependent RNA polymerase with high affinity, blocking viral RNA synthesis and thereby suppressing viral replication. This target has strong specificity, with an IC50 value as low as 18 nM, demonstrating excellent antiviral efficacy.
Acetifol possesses relatively ideal druggability parameters. Its molecular weight (288.2550) and LogP (1.8614) conform to the Lipinski rule, suggesting promising oral bioavailability potential. TPSA is 107.22 Ų, slightly above the ideal range, but still expected to optimize absorption characteristics through structural modification. Low water solubility (0.3033 mg/mL) is a major bottleneck in formulation development, which can be improved through technologies such as nanocarriers and solid dispersions.
The blood-brain barrier has a relatively low penetration capacity, limiting its application in central nervous system diseases, but it helps reduce central side effects. In terms of safety, no hERG channel inhibition was observed, the risk of genotoxicity was low, and it met clinical drug safety standards.
Pharmacokinetic studies show that sacrosol is absorbed orally relatively quickly, has a moderate plasma half-life, and is mainly metabolized by the liver, with most metabolites being glucuronic acid conjugates. Renal excretion is the main clearance route. Future research on in vivo pharmacokinetics and toxicology systems is needed to clarify their metabolic stability and potential drug interactions.
With its multi-target and multi-mechanism pharmacological activity, sacrofenol demonstrates broad clinical application prospects in anti-tumor, antiviral, and anti-inflammatory fields. In particular, as a highly effective inhibitor of influenza virus RNA polymerase, it provides a new molecular framework and mechanism of action for the development of anti-influenza drugs. In terms of anti-tumor treatment, satrin can become a novel candidate for adjuvant chemotherapy or targeted therapy by modulating multiple key targets.
However, the low water solubility and limited bioavailability of sacrophilol are the main obstacles to its clinical translation. Future research should focus on structural optimization, dosage form innovation, and combination therapy strategies to enhance efficacy and safety. Additionally, in-depth analysis of its molecular mechanisms and metabolic pathways in vivo helps accurately target indications and formulate reasonable clinical development plans.
With continuous advances in natural product pharmacology and medicinal chemistry technologies, sacrofenol is expected to become an important representative of natural flavonoid drug development, providing new ideas and methods for treating various diseases.
As a natural flavonoid compound with significant antioxidant, anti-inflammatory, antiviral, and antitumor activities, Sanctol demonstrates multi-target, multi-mechanism pharmacological properties and a solid safety foundation. It exerts broad biological effects by inducing the Nrf2 signaling pathway and inhibiting key targets such as influenza virus RNA polymerase. Despite challenges in water solubility and bioavailability, its excellent pharmacological activity and druggability parameters provide a solid foundation for clinical application.
In the future, by combining modern drug design and formulation technology, sacrofen is expected to successfully transform from a natural product into a clinical drug, becoming an effective candidate for treating various diseases. Ongoing basic and applied research will drive its in-depth development in the field of natural product pharmacology, fostering innovation and application of natural flavonoid drugs.
Shenshuai
Wenjing
Hedandan
